Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria
Background: Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potentially preclude/pre-empt the detection of subsequent recrudescence of persistent, sub-microscopic primary infections. M...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
05 July 2019
|
| In: |
Malaria journal
Year: 2019, Volume: 18 |
| ISSN: | 1475-2875 |
| DOI: | 10.1186/s12936-019-2837-4 |
| Online Access: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1186/s12936-019-2837-4
|
| Author Notes: | The WorldWide Antimalarial Resistance Network Methodology Study Group. Prabin Dahal ... Steffen Borrmann [und 111 weitere] |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1677939923 | ||
| 003 | DE-627 | ||
| 005 | 20230428021908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190930s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12936-019-2837-4 |2 doi | |
| 035 | |a (DE-627)1677939923 | ||
| 035 | |a (DE-599)KXP1677939923 | ||
| 035 | |a (OCoLC)1341244760 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dahal, Prabin |e VerfasserIn |0 (DE-588)1196053278 |0 (DE-627)1677942991 |4 aut | |
| 245 | 1 | 0 | |a Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria |c The WorldWide Antimalarial Resistance Network Methodology Study Group. Prabin Dahal ... Steffen Borrmann [und 111 weitere] |
| 264 | 1 | |c 05 July 2019 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.09.2019 | ||
| 520 | |a Background: Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potentially preclude/pre-empt the detection of subsequent recrudescence of persistent, sub-microscopic primary infections. Methods: Antimalarial studies typically report the risk of recrudescence derived using the Kaplan–Meier (K–M) method, which considers new infections acquired during the follow-up period as censored. Cumulative Incidence Function (CIF) provides an alternative approach for handling new infections, which accounts for them as a competing risk event. The complement of the estimate derived using the K–M method (1 minus K–M), and the CIF were used to derive the risk of recrudescence at the end of the follow-up period using data from studies collated in the WorldWide Antimalarial Resistance Network data repository. Absolute differences in the failure estimates derived using these two methods were quantified. In comparative studies, the equality of two K–M curves was assessed using the log-rank test, and the equality of CIFs using Gray’s k-sample test (both at 5% level of significance). Two different regression modelling strategies for recrudescence were considered: cause-specific Cox model and Fine and Gray’s sub-distributional hazard model. Results: Data were available from 92 studies (233 treatment arms, 31,379 patients) conducted between 1996 and 2014. At the end of follow-up, the median absolute overestimation in the estimated risk of cumulative recrudescence by using 1 minus K–M approach was 0.04% (interquartile range (IQR): 0.00–0.27%, Range: 0.00–3.60%). The overestimation was correlated positively with the proportion of patients with recrudescence [Pearson’s correlation coefficient (ρ): 0.38, 95% Confidence Interval (CI) 0.30–0.46] or new infection [ρ: 0.43; 95% CI 0.35–0.54]. In three study arms, the point estimates of failure were greater than 10% (the WHO threshold for withdrawing antimalarials) when the K–M method was used, but remained below 10% when using the CIF approach, but the 95% confidence interval included this threshold. Conclusions: The 1 minus K–M method resulted in a marginal overestimation of recrudescence that became increasingly pronounced as antimalarial efficacy declined, particularly when the observed proportion of new infection was high. The CIF approach provides an alternative approach for derivation of failure estimates in antimalarial trials, particularly in high transmission settings. | ||
| 700 | 1 | |a Borrmann, Steffen |d 1970- |e VerfasserIn |0 (DE-588)12075293X |0 (DE-627)704966425 |0 (DE-576)29236900X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Malaria journal |d London : BioMed Central, 2002 |g 18(2019) Artikel-Nummer 225, 14 Seiten |h Online-Ressource |w (DE-627)355986582 |w (DE-600)2091229-8 |w (DE-576)107015196 |x 1475-2875 |7 nnas |a Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria |
| 773 | 1 | 8 | |g volume:18 |g year:2019 |g extent:9 |a Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12936-019-2837-4 |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190930 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 12075293X |a Borrmann, Steffen |m 12075293X:Borrmann, Steffen |d 910000 |d 911700 |e 910000PB12075293X |e 911700PB12075293X |k 0/910000/ |k 1/910000/911700/ |p 15 | ||
| 999 | |a KXP-PPN1677939923 |e 3519119129 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 30.09.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1677939923","person":[{"roleDisplay":"VerfasserIn","display":"Dahal, Prabin","role":"aut","family":"Dahal","given":"Prabin"},{"display":"Borrmann, Steffen","roleDisplay":"VerfasserIn","role":"aut","family":"Borrmann","given":"Steffen"}],"title":[{"title":"Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria","title_sort":"Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria"}],"physDesc":[{"extent":"9 S."}],"relHost":[{"part":{"extent":"9","volume":"18","text":"18(2019) Artikel-Nummer 225, 14 Seiten","year":"2019"},"pubHistory":["1.2002 -"],"language":["eng"],"recId":"355986582","note":["Gesehen am 23.06.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malariaMalaria journal","title":[{"title_sort":"Malaria journal","subtitle":"published in collaboration with the Liverpool School of Tropical Medicine","title":"Malaria journal"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["355986582"],"zdb":["2091229-8"],"issn":["1475-2875"]},"origin":[{"dateIssuedDisp":"2002-","publisher":"BioMed Central","dateIssuedKey":"2002","publisherPlace":"London"}]}],"name":{"displayForm":["The WorldWide Antimalarial Resistance Network Methodology Study Group. Prabin Dahal ... Steffen Borrmann [und 111 weitere]"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"05 July 2019"}],"id":{"eki":["1677939923"],"doi":["10.1186/s12936-019-2837-4"]}} | ||
| SRT | |a DAHALPRABICOMPETINGR0520 | ||